The purpose of this study is to evaluate the efficacy and the safety of Risedronate, cholecalciferol combination tablet in patients with Osteoporosis
The purpose of this study is to evaluate the efficacy and the safety of Monthly Risedronate with cholecalciferol on 25 Hydroxyvitamin D level and bone markers patients with osteoporosis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
150
Chung-ang university hospital
Seoul, South Korea
proportion of patients with 25(OH)D level < 20 ng/mL at 16 weeks.
Time frame: 16 weeks form first drug adminstration.
proportion of patients with 25(OH)D level < 9 ng/mL at 16 weeks, change of 25(OH)D level and Bone Markers.
Secondary end point is : 1. proportion of patients with 25(OH)D level \< 9 ng/mL at 16 weeks 2. change of 25(OH)D level 3. change of BSAP 4. change of CTX 5. change of Ca 6. change of phosphorous 7. change of PTH 8. change of 8-foot walking test, Sit-To-Stand test
Time frame: 16 weeks form first drug administration.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.